NCT07113418Not yet recruiting
Role of FGF21 in Breast Cancer
Role of Fibroblast Growth Factor 21(FGF21) in Breast Cancer
Source: ClinicalTrials.gov · Last updated 8 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The present study aims to evaluate the serum level of FGF-21 in patients with breast cancer and its correlation with clinical, laboratory, and pathological data.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 84 (estimated)
- First submitted
- 22 Jul 2025
- Start date
- Sept 2025
- Primary completion date
- Sept 2026
- Lead sponsor
- Assiut University
- Diseases
- Childhood cancers
- NCT number
- NCT07113418
What you commit to
- Study type: Observational
- Planned participants: 84
- From Sept 2025 to the primary completion date, Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- \-
Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assuit university ( South Egypt Cancer Institute ) Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.